I'm curious as to what's pushing OGC's recent SP performance... volume up too. Hmmm, this hasn't happened in a while! Baron
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
Week 32 Wrap: AI is clearly overhyped – but did we see ‘bubble’ burst already? Plus RBA decision; Japan’s wild week & Google ruling